Renal drug transporters and their significance in drug-drug interactions

被引:140
作者
Yin, Jia [1 ]
Wang, Joanne [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, H272J Hlth Sci Bldg, Seattle, WA 98195 USA
关键词
Renal drug transporters; Drug-drug interactions; Organic cations; Organic anions; Nephrotoxicity; ORGANIC ANION TRANSPORTER; CISPLATIN-INDUCED NEPHROTOXICITY; MULTIDRUG-RESISTANCE PROTEINS; INTESTINAL P-GLYCOPROTEIN; KIDNEY PROXIMAL TUBULES; CATION TRANSPORTER-2; FUNCTIONAL-CHARACTERIZATION; CLINICAL PHARMACOKINETICS; MOLECULAR-IDENTIFICATION; TISSUE DISTRIBUTION;
D O I
10.1016/j.apsb.2016.07.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The kidney is a vital organ for the elimination of therapeutic drugs and their metabolites. Renal drug transporters, which are primarily located in the renal proximal tubules, play an important role in tubular secretion and reabsorption of drug molecules in the kidney. Tubular secretion is characterized by high clearance capacities, broad substrate specificities, and distinct charge selectivity for organic cations and anions. In the past two decades, substantial progress has been made in understanding the roles of transporters in drug disposition, efficacy, toxicity and drug-drug interactions (DDIs). In the kidney, several transporters are involved in renal handling of organic cation (OC) and organic anion (OA) drugs. These transporters are increasingly recognized as the target for clinically significant DDIs. This review focuses on the functional characteristics of major human renal drug transporters and their involvement in clinically significant DDIs. (C) 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
引用
收藏
页码:363 / 373
页数:11
相关论文
共 50 条
[21]   Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments [J].
Fokter, Nina ;
Mozina, Martin ;
Brvar, Miran .
WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (3-4) :81-88
[22]   Drug-drug Interactions of Angiotensin Converting Enzyme Inhibitors Mediated by Metabolizing Enzymes and Transporters [J].
Sun, Pengyuan ;
Liu, Kexin .
CURRENT DRUG METABOLISM, 2018, 19 (13) :1119-1129
[23]   Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant? [J].
Lepist, Eve-Irene ;
Ray, Adrian S. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 :S73-S81
[24]   Anti hypertensive drug-drug interactions [J].
Morales-Olivas, FJ ;
Estañ, L .
MEDICINA CLINICA, 2005, 124 (20) :782-789
[25]   Drug-drug interactions of β-adrenoceptor blockers [J].
Brodde, OE ;
Kroemer, HK .
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2003, 53 (12) :814-822
[26]   Drug-drug interactions.: An update [J].
Morales-Olivas, Francisco J. ;
Estan, Luis .
MEDICINA CLINICA, 2006, 127 (07) :269-275
[27]   Drug-Drug Interactions in Headache Medicine [J].
Ansari, Hossein ;
Ziad, Sanaz .
HEADACHE, 2016, 56 (07) :1241-1248
[28]   Evaluation of drug-drug interactions with fesoterodine [J].
Malhotra, Bimal ;
Sachse, Richard ;
Wood, Nolan .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (06) :551-560
[29]   A Review of Daclatasvir Drug-Drug Interactions [J].
Garimella, Tushar ;
You, Xiaoli ;
Wang, Reena ;
Huang, Shu-Pang ;
Kandoussi, Hamza ;
Bifano, Marc ;
Bertz, Richard ;
Eley, Timothy .
ADVANCES IN THERAPY, 2016, 33 (11) :1867-1884
[30]   Measuring drug similarity using drug-drug interactions [J].
Lv, Ji ;
Liu, Guixia ;
Ju, Yuan ;
Huang, Houhou ;
Sun, Ying .
QUANTITATIVE BIOLOGY, 2024, 12 (02) :164-172